Invivyd Inc. announced preliminary fourth quarter 2025 results, reporting PEMGARDA® (pemivibart) net product revenue of $17.2 million, reflecting a 25% increase year-over-year and a 31% increase quarter-over-quarter. The company ended 2025 with cash and cash equivalents of $226.7 million, following the raising of over $200 million through financing transactions in the second half of the year. Invivyd also reported 281,987,033 shares of common stock outstanding as of December 31, 2025, excluding 27,342,442 pre-funded warrants. The company highlighted the initiation of the DECLARATION Phase 3 clinical trial for its vaccine-alternative antibody VYD2311 for COVID-19 prevention, with top-line data expected in mid-2026 and Fast Track designation granted by the FDA in December 2025. Additional pipeline updates included the nomination of RSV antibody VBY329 for preclinical development and plans for selecting a preclinical measles monoclonal antibody candidate in the first half of 2026. Further updates are expected in conjunction with the company’s Form 10-K filing and future quarterly reporting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621848) on January 08, 2026, and is solely responsible for the information contained therein.